Inlyta axitinib regulatory update

Germany's Statutory Health Insurance Funds Association (GKV-Spitzenverband) and Pfizer completed pricing negotiations for Inlyta axitinib to treat advanced renal cell carcinoma (RCC) in patients who failed treatment with a cytokine. Pfizer said the reimbursed price will be effective on Oct. 1, but declined to comment on the details of the pricing negotiations. ...